Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME^® trial.

ABSTRACT:

Aims/introduction

In the EMPA-REG OUTCOME^® trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes and established cardiovascular disease. This exploratory analysis investigated the effects of empagliflozin on the kidneys in Asian patients.

Materials and methods

Participants in the EMPA-REG OUTCOME^® trial were randomized (1:1:1) to empagliflozin 10 mg, 25 mg or a placebo. In patients of Asian race, we analyzed incident or worsening nephropathy (progression to macroalbuminuria, doubling of serum creatinine, initiation of renal-replacement therapy or renal death) and its components, estimated glomerular filtrat

SUBMITTER: Kadowaki T 

PROVIDER: S-EPMC6497612 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature